Cannex Capital Completes Strategic Investment Into Soma Group, An Innovative New Zealand Cannabis-Focused Startup

This information was provided by Kavi Mohan

Send your Press Release here.

Investment expands international cannabis strategy

Vancouver, BC / TheNewswire / November 1, 2018 – Cannex Capital Holdings Inc. (“Cannex” or the “Company”) (CSE: CNNX / OTCQX: CNXXF)is pleased to announce that Cannex has acquired a 10% founding ownership interest for US$750,000 in Soma Group Holdings Inc. (“Soma”), a New Zealand-based cannabis start-up. Soma have an innovative science-based cannabinoid R&D and production platform and represent an important first step in Cannex’s international intellectual property development strategy.

As a part of the Soma initiative, Greg Marshall has stepped down from the Cannex Capital board to join Soma as a founding director. He will work closely with Soma’s CEO Mike Healy, a 25-year veteran of the global life sciences industry and was, for the past nine years, CFO of Apotex Australia and Asia Pacific. Cannex thanks Mr. Marshall for his efforts during the Company’s formative stages and welcomes the opportunity to work with him in his new role at Soma and as an advisor to the Cannex board.

Soma is pursuing a three-pronged approach to creating a leading cannabis business beginning with an R&D partnership with the New Zealand government to create world-class cannabis genetics for worldwide licensing,” said Mr. Marshall. “Secondly, we’re acquiring a profitable, GMP certified food processing facility in Australia from Coca Cola Amitil to manufacture nutraceutical terpene-enhanced products for Asian Pacific distribution and will use this facility for cannabis production once licensing is in place. Lastly, we will acquire Vaporium, a New Zealand e-cigarette online and physical retailer which will eventually form the backbone of our retail cannabis strategy.”

Leading the Soma effort as CEO will be Mike Healey, a 25-year veteran of global pharmaceutical giant Apotex. Joining him will be Dr. Anna Campbell, who currently serves as a Director of Abacus Bio, a world-leading agricultural science company with operations in New Zealand and Scotland, specializing in strain stabilization and commercialization.

As the global cannabis market matures we expect to see increased demand for products with performance claims backed by credible fact-based science,” said Mr. Healey. “This is standard for the life and health sciences industry and I look forward to applying disciplines and best practices utilized at Apotex to position Soma with a competitive advantage as demand grows and consumers are faced with a wider choice of cannabinoid-based medicines, nutraceuticals and functional foods.”

“Cannex is excited to be partnering with Soma, led by Mike Healy, an exceptional global healthcare executive, who are poised to create a truly synergistic set of cannabis assets,” said Cannex Chairman, Roman Tkachenko. “The cannabis market is evolving rapidly and while Cannex has a primary focus on the North American adult use cannabis market, we are excited to be involved with Soma and look forward to supporting their growth and development.”

Soma’s science program will be headquartered in Dunedin, New Zealand. Soma has recently signed an agreement with the New Zealand Government’s Plant & Food Research group, a government-owned Crown Research Institute. Together, they will characterize and map the genetic profile of local cannabis strains for potential medical uses.

Soma’s production base is in the fruit growing region of Goulburn, Victoria State, Australia and includes a food processing and production operation recently acquired from Coca Cola Amatil. The operation comprises of a 77,000 m2 production facility and a profitable food production business, IXL Jams and Taylors Sauces and Marinades that Soma reports generates audited EBITDA of A$2.5 million. Coca Cola Amatil will continue to provide distribution for existing products, providing cashflow for the development of Soma’s terpene and cannabinoid product pipeline.

Emerald contributor since March 2012


Your email address will not be published.